Skip to search formSkip to main contentSkip to account menu

galeterone

Known as: Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-, Specific Androgen Receptor Modulator/CYP17 Lyase Inhibitor TOK-001 
An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Narrower (1)

TOK-001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Emerging data on androgen receptor splice variants in prostate cancer.
Androgen receptor splice variants are alternatively spliced variants of androgen receptor, which are C-terminally truncated and… 
Review
2016
Review
2016
Galeterone for the treatment of advanced prostate cancer: the evidence to date
Major advances have been achieved recently in the treatment of metastatic castration-resistant prostate cancer, resulting in… 
2016
2016
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Highly Cited
2015
Highly Cited
2015
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase (CYP17), the key enzyme which catalyzes… 
Highly Cited
2015
Highly Cited
2015
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo
Galeterone (Gal) is a first-in-class multi-target oral small molecule that will soon enter pivotal phase III clinical trials in… 
Review
2015
Review
2015
CYP17A1 inhibitors in castration-resistant prostate cancer
Highly Cited
2014
Highly Cited
2014
Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
Purpose: Galeterone inhibits the enzyme CYP17A1 and is currently in phase II clinical trials for castration-resistant prostate… 
Review
2013
Review
2013
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Highly Cited
2013
Highly Cited
2013
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate…
As part of our program to explore the influence of small structural modifications of our drug candidate 3β-(hydroxy)-17-(1H… 
Review
2012
Review
2012
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.
Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (crpc), a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)